Control Bionics (ASX:CBL) Total Liabilities: A$2.20 Mil (As of Dec. 2025)


What is Control Bionics Total Liabilities?

Control Bionics ASX:CBL -5.13% Total Liabilities is A$2.20 Mil as of Dec. 2025. The stock has 6 warning signs investors should review.

Control Bionics's Total Liabilities for the quarter that ended in Dec. 2025 was A$2.20 Mil.

Control Bionics's quarterly Total Liabilities increased from Dec. 2024 (A$2.38 Mil) to Jun. 2025 (A$2.72 Mil) but then declined from Jun. 2025 (A$2.72 Mil) to Dec. 2025 (A$2.20 Mil).

Control Bionics's annual Total Liabilities increased from Jun. 2023 (A$1.55 Mil) to Jun. 2024 (A$2.76 Mil) but then declined from Jun. 2024 (A$2.76 Mil) to Jun. 2025 (A$2.72 Mil).

Control Bionics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Control Bionics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Control Bionics Total Liabilities Chart

Control Bionics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Liabilities
Get a 7-Day Free Trial 1.19 1.51 1.55 2.76 2.72

Control Bionics Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.22 2.76 2.38 2.72 2.20

Control Bionics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Control Bionics's Total Liabilities for the fiscal year that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.553+(0.134+2.5673907444457E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.037+0)
=2.72

Total Liabilities=Total Assets (A: Jun. 2025 )-Total Equity (A: Jun. 2025 )
=8.233-5.509
=2.72

Control Bionics's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.161+(0.02+0.023
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.20

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=9.933-7.729
=2.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of A$2.20 Mil mean?
Control Bionics (ASX:CBL) has a Total Liabilities of A$2.20 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Control Bionics and its competitors.
Is Control Bionics' Total Liabilities too high?
Control Bionics' current Total Liabilities is A$2.20 Mil.
How does Control Bionics' Total Liabilities compare to ABT and SYK?
Control Bionics' Total Liabilities of A$2.20 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Devices & Instruments company?
A good Total Liabilities depends on the Medical Devices & Instruments industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Control Bionics and its competitors. Control Bionics's current Total Liabilities is A$2.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.07 — trading 146.7% above its estimated fair value. The current Total Liabilities is A$2.20 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current Total Liabilities is A$2.20 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Control Bionics Business Description

Address 11-13 Pearson Street, Level 4, Cremorne, VIC, AUS, 3121
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.